Fuchs Endothelial Corneal Dystrophy
Ophthalmology
2
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
Design TherapeuticsDT-168
SantenSTN1010904 ophthalmic suspension 0.03% BID
Heidelberg PharmaDuration of Supine Positioning
Clinical Trials (3)
Total enrollment: 188 patients across 3 trials
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Start: Jul 2025Est. completion: Dec 2026
Phase 2Recruiting
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
Start: May 2022Est. completion: May 202586 patients
Phase 2Completed
Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK)
Start: Oct 2025Est. completion: Mar 2027102 patients
N/ARecruiting
Related Jobs in Ophthalmology
Lead Data Manager
Genomics
Remote
10h ago
Cleanroom and Laboratory Technician
SAB BIO
10h ago
Material Handler - 8 Hour Day Shift
Pfizer
United States - Kansas - McPherson
Yesterday
Senior Process Technician - Rotating 2nd Shift
Pfizer
United States - Massachusetts - Andover
Yesterday
$27 - $45/hr
Staff Equipment and Systems Engineer
Johnson & Johnson
Plymouth, Minnesota, United States of America
Yesterday
$94K - $152K/yr
APAC Regulatory Affairs Manager
Johnson & Johnson
Singapore, Singapore
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 188 patients
3 companies competing in this space